NFL Network's Daniel Jeremiah believes that running back Ashton Jeanty should be a possible target for the Patriots with the ...

Shares of Texas-based biotechnology company Cassava Sciences, Inc. (SAVA) tumbled 33% on Tuesday after the company reported ...

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

The Canucks and the Islanders are borderline playoff teams thanks to their head coaches Rick Tocchet and Patrick Roy.

Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's diseaseSimufilam continued to dem ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...

Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed ...

The legislative committee mulling how to help implement Nebraska’s voter-led medical cannabis laws awaits an amendment before ...